Yao Li, M.D. and MSc., the Head of Medical Affairs and Pharmacovigilance at Bayer Healthcare China including Hong Kong.  In this role, she directs the Medical Affairs, Medical Science Liaisons, Medical Communications, Scientific Operations, Medical Compliance, Patient Support and Disease Management Programs, Health Economics and Outcome Research and Pharmacovigilance.

Prior to this position, Yao has more than 15 years of experience in Medical Affairs with progressively increasing responsibilities across multiple therapeutic areas. She held positions in different therapeutic areas including Cardiovascular, Metabolism, Oncology, Gynecology, Ophthalmology, Anti-infection and Hemophilia at Xi’an-Janssen, Novartis, Bayer China and Bayer US. She received her medical education at Capital Medical University and Peking Union Medical College.

Dr. Lang is the Vice President and Head of International Medical Affairs and Oncology Clinical Development Asia-Pacific at Gilead Sciences. In this role, Zig oversees the Medical Affairs teams in countries and regions outsides of the US and Europe. He also leads the Oncology Clinical Development in the Asia-Pacific region.
Prior to coming to Gilead Sciences, Zig worked in Bayer’s Global Medical Affairs and Pharmacovigilance in the US and China. Zig has over 23 years of pharmaceutical industry experiences ranging from early and late stage clinical development to medical affairs. Zig held positions with increasing responsibilities at Bayer, Endo Pharmaceuticals, Johnson and Johnson, Wyeth and Novo Nordisk. Zig is a board-certified oncologist and hematologist in the US. He received his medical education at the Fourth Military Medical University in Xi’an and PhD in Biochemistry at Rush University in Chicago.